Assolombarda, headed by the Deputy Chairman delegated for Life Sciences, Sergio Dompé, has set up a significant network of ties around the world in recent years, with a view to launching international-type partnerships on matters of health and innovation in the health sector. Many initiatives have been put together in this regard to connect worldwide best practices. The aim is to facilitate the mutual exchange of skills, aware of the need to systemise the best experiences in order to deal with challenges dictated by the times via cross-border strategic alliances.  

Here, Assolombarda has instituted a vast array of activities and agreements aimed at bolstering alliances with the countries in the Gulf area. In 2020 these culminated by taking part in Expo Dubai, on which occasion the Association launched an international “Life Science - Gulf Area” project — an initiative aimed at identifying new opportunities for dialogue and discussion between the Lombard and Italian health sector and national departments in the Gulf Countries, starting with Saudi Arabia. This commitment on the part of Assolombarda characterised all six months of the Expo and has gone on, up to now, consolidating relationships developed between the respective companies, in part thanks to the support provided by Italian institutions, in particular the diplomatic backing of ICE and SACE.  

Related: Webinar: Digitalisation creates a collaborative environment in Saudi healthcare

The wish to continue to collaborate with these countries is driven by the companies' interest in a country that is growing strongly: Saudi Arabia, which for its part, is applying its “Saudi Vision 2030” to launch an ambitious plan for economic and social reform and development, working at some levels and in strategic sectors: development in health, privatisation of services, and international partnerships. For Lombardy and Italy, the launching of a project structured in this way provides a unique opportunity to be seen as a chance to share respective skills based on a fruitful, sound, and long-lasting friendship. The setting up of a network that has made the creation of two international forums possible, promoted with the aim of strengthening ties between our countries, should be looked at in this way.  

But that is not all. The activation of a collaboration agreement with one of the leading health operators in KSA, the National Care Company, has allowed businesses in Lombardy and Italy to be involved in setting up partnerships and taking part in government tenders precisely associated with the "Saudi Vision 2030".  A wealth of contacts has given rise to fruitful dialogue with some stakeholders interested in our Lombard companies, with a view to implementing the Saudi plan on the ground in relation to the health system. For example, the National Care Company Group is negotiating and taking part in dialogues with Vivisol on the question of integrated home care, and at the same time, with the Centro Clinico NeMO for highly complex rehabilitation. The aim is to propose other Lombard businesses that can act as international partners. 

The synergy created by Assolombarda with Saudi Arabia has also given rise to a “Saudi Italian Forum” — an occasion to spread the partnership to other sectors, including furnishing and lighting, fashion, construction materials, and energy. In addition, on 4 September this year, Assolombarda collaborated in organising the Italian-Saudi Investments Forum in Milan, promoted jointly by the Saudi Investments Ministry and the Industry and Made in Italy Ministry. The programme included heads of the departments involved: representatives of Humanitas, Gruppo San Donato, and Dompé, who were invited to join the panel dedicated to healthcare and pharma as speakers. Overall, the Forum recorded 1,200 attendees, including 200 Saudi companies. 

Capitalising on its previous successes, Assolombarda intends to continue to facilitate relations and meetings, to affirm Italy's excellence in the Gulf countries: the mission to Riyadh in Saudi Arabia, planned for October and November 2024, is part of this. It will be dedicated to companies and structures in the Life Science sector on the occasion of the Global Health Exhibition. This Exhibition is expected to involve some of the main hospitals and private clinics, as well as companies and start-ups.  

On that occasion, in light of an agreement signed with SDA Bocconi, the Association will present the training offered by the Leading Business School in Italy and worldwide excellence in managerial training for the Health Care sector, including Masters programmes, Executive Open Programmes, and skills in designing and implementing custom-made programmes for medical doctors, managers, and employees of public and private health structures.  

Related: Saudi Arabia marks progress in accessible healthcare

During the mission, Professor Francesca Lecci, Director of SDA Bocconi Master in Healthcare Management, will attend numerous meetings and an important round table at the Global Health Exhibition, presenting the contribution that SDA Bocconi can make to supporting continuous growth in the health systems in the Gulf area. In fact, with more than 50 years’ experience in health management behind them, backed by great attention to research and constant striving for didactic innovation, SDA Bocconi designs and runs research and managerial training programmes that are able to support institutions, companies, and individuals, with framing and managing the great challenges that characterise health systems worldwide. From the need to optimise the allocation of economic, financial, and natural resources to the importance of designing processes and services that are able to guarantee high-quality assistance. From the big questions posed by integrating technology and computerising health care to the question about how to plan and implement efficacious policies. From the relevance of stimulating constant collaboration and interaction between various disciplines and different stakeholders to the crucial aspect of being able to construct models to measure the value generated for patients, caregivers, and the system as a whole.  

The contacts forged, and agreements already stipulated have given rise to a full agenda that provides for meetings with stakeholders, ministries, and regulatory bodies in the Gulf, open to possible partnerships and collaborations with Lombard companies in the healthcare sector and the Management School at Bocconi University. 

Much more awaits at the Global Health Exhibition in Riyadh this year. Register now to learn, network, and lead your business and practice into a revolutionary healthcare market. 

Back to Management

Fibromyalgia, a complex and debilitating chronic pain disorder, is underdiagnosed despite its global impact. The rising incidence of fibromyalgia can be attributed to various factors, such as limited medical awareness, evolving diagnosis criteria, ongoing research progress, and the influence of environmental factors. This underscores the urgent need to address the significant gaps in its treatment options. The fibromyalgia treatment market presents both challenges and opportunities that require immediate attention. 

The fibromyalgia treatment landscape 

Fibromyalgia is often misunderstood and misdiagnosed. It is characterised by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction. This challenging condition presents complex symptoms that baffle medical professionals and researchers. It involves pain that extends beyond typical physical boundaries, resulting in pervasive discomfort without clear explanations. This discomfort is frequently coupled with profound fatigue, making everyday tasks a challenge, and significantly impacting the lives of those living with it. 

Related: Grasping the economic cost of chronic pain

Patients and healthcare experts face the ongoing challenge of managing its symptoms. Researchers continue their diligent efforts to explore potential treatments and better understand the condition, offering hope for improved quality of life. 

Personalised treatment: the need of the hour 

One size does not fit all when it comes to fibromyalgia treatment. Each patient's condition experience is unique, and what works for one individual may not be effective for another. This calls for a personalised treatment approach considering the patient's specific symptoms, lifestyle, and preferences. Personalisation in fibromyalgia treatment entails customising interventions, whether pharmaceutical, lifestyle-based, or alternative therapies, to suit each patient. Advances in technology, such as assessment tools and digital health applications, offer promising prospects for identifying the most effective treatment strategies for each patient. 

However, developing personalised treatment options for fibromyalgia comes with challenges. Research in this field is still in its infancy, and comprehensive data and standardised diagnostic criteria are lacking. Investors willing to support the development of personalised solutions must navigate this uncertainty, making it a challenging venture. 

Investor challenges: technical and financial 

Investing in the fibromyalgia treatment market requires a realistic understanding of the significant challenges involved. From a technical perspective, the challenges are quite complex. They involve the need for well-designed and meticulously conducted clinical trials, pinpointing specific factors that can customise treatments for individual patients and creating innovative therapies that can effectively tackle the varied symptoms of Fibromyalgia. Since the condition varies from person to person, finding a universal "one-size-fits-all" treatment is difficult, requiring a thorough and personalised approach that considers each patient's distinct requirements and reactions. 

Additionally, investors often struggle with the need for significant funding to support research and development efforts for Fibromyalgia treatments. This financial burden is compounded by the limited awareness and persistent stigma associated with the condition, making attracting investment capital quite challenging. Moreover, the protracted nature of clinical trials, often spanning several years, and their inherently unpredictable outcomes may discourage those investors from seeking swift returns on their investments. 

Related: World Arthritis Day highlights innovative treatments

Considering these multifaceted challenges, investors keen on making a meaningful impact in this critical area of healthcare must consider fostering collaborations between researchers, healthcare providers, and technology enterprises. Such partnerships can lead to more comprehensive and data-driven approaches to understanding and treating fibromyalgia. Additionally, advocating for governmental support through grants and incentives is vital, as these measures can stimulate more significant investment in the pursuit of effective fibromyalgia treatments, ultimately benefitting both patients and the broader healthcare ecosystem. 

Expanding insurance coverage for fibromyalgia treatments 

Insurance coverage for fibromyalgia treatments is another pressing issue. Many insurance plans worldwide cover only a limited range of pharmaceutical or injection-based treatments. This narrow approach can leave patients without access to alternative, often more effective treatments. 

One example of such an emerging treatment is Hyperbaric Oxygen Therapy. Some studies have suggested that HBOT can provide significant symptom relief for fibromyalgia patients. However, the cost of HBOT sessions for treating Fibromyalgia is currently not covered by insurance, leaving many patients unable to afford this potentially life-changing treatment. 

There is a need for insurance reform to ensure that fibromyalgia patients have access to a broader range of treatments. This reform should also address the financial burden on patients, who often must pay out of pocket for treatments not covered by insurance. 

A multidisciplinary approach to fibromyalgia care 

In addition to personalised treatments and expanded insurance coverage, a multidisciplinary approach to fibromyalgia care is essential. Fibromyalgia is not just about physical pain; it also affects mental health. Psychological support services, such as therapy and counselling, should be integral to the treatment plan. 

Fibromyalgia patients often struggle with depression, anxiety, and the psychological impact of living with a chronic condition. Providing access to mental health professionals who understand the unique challenges of fibromyalgia can significantly improve patients' overall well-being and treatment outcomes. 

Employers are pivotal in influencing the well-being of individuals with fibromyalgia. Employers can provide valuable support by offering flexible work arrangements, such as remote work options, or by creating comfortable work environments that accommodate the unique needs of employees with fibromyalgia. Addressing sick leave policies to accommodate flare-ups and the condition's unpredictability is also crucial. However, when employers fail to provide such support, it can perpetuate a detrimental cycle.  

Without the necessary workplace accommodations, individuals may face difficulties accessing costly treatments, resulting in worsened symptoms, increased mental health challenges, heightened pain, and reduced quality of life. Therefore, fostering a supportive work environment is essential in alleviating the burden of fibromyalgia for affected individuals. 

Dr. Mouzayan Ginzarly is a Family Medicine Consultant at Aviv Clinics Dubai. 

 

Get the latest insights from the healthcare industry straight to your inbox. Subscribe for a bi-weekly roundup of the latest healthcare tech, trends, innovation and patient experience, accompanied by exclusive interviews from the industry’s leaders.

___

 

Back to Management

 

Every year, over 310 million major surgical procedures are performed worldwide, with approximately 40 to 50 million in the US alone. These procedures are costly based on the resources, time and services provided, but innovation has introduced ways to effectively reduce expenses for both clinicians and patients. It further extends to cover surgical pathways and advanced training simulations using immersive technology. 

According to an analysis from US federal government actuaries, surgery accounts for up to US$1 trillion or 30 per cent in costs, making it an expensive part of the US$3.65-trillion healthcare system in the US. The overall yearly cost of elective inpatient and outpatient surgical procedures in the US is projected to be US$147.2 billion, with total hospital reimbursement ranging from US$195.4 to US$212.2 billion. 

The cost of surgical procedures at in-network hospitals alone is significantly higher than at independent hospitals, reports a recent study titled ‘Evaluation of Prices for Surgical Procedures Within and Outside Hospital Networks in the US’ published in the JAMA Network Open. Innovation, however, has been pivotal to maintaining its affordability. New technologies have also left an impact on the efficiency and improvement of the surgery itself. Digitising surgical processes and developing collaborative tools can help hospitals to better manage resources. 

Related: Insurtech chatbots: Synergised digital solution for enhancing patient experience

Findings from the same study also show that the automation of various surgical workflows and processes saves an average of US$78 on expenses related to medical and surgical supplies. The prices varied greatly between categories, surgeons, and hospitals. 

Experts Dr. Roderick Dunn, Chair of the Division of Plastic and Reconstructive Surgery, Sheikh Shakhbout Medical City Abu Dhabi (SSMC), and Dr. Sumit Verma, MBBS, Head – Provider Management, INAYAH TPA (NLGIC Group), share insights on how innovation can help reduce surgical costs. 

The role of innovation in surgery 

Cutting-edge techniques, such as minimally invasive procedures, AI and robot-assisted surgery and personalised treatments are examples of technologies that aid in creating a faster and swift patient experience, says Dr. Dunn. According to Dr. Verma, the advances in surgical procedures have also noted increased conversations around its cost-effectiveness among the health community. 

"The overall cost of technological procurement for healthcare providers is very high, including maintenance costs. When patients are treated with advanced technology, the outcomes have shown advantages in areas of reduced hospital stay, lower rate of hospital-acquired infection, a faster rate of recovery from the illness, reduction in postoperative care, and modification of post-surgical treatment in cases of ailments such as oncology," says Dr. Verma. 

The link between surgeons and surgical costs 

Surgeons have considerable influence over resource allocation but possess poor knowledge of healthcare costs, according to ‘A study evaluating cost awareness amongst surgeons in a health service under financial strain’. An investigation by the JAMA Surgery, titled ‘Association Between Surgeon Scorecard Use and Operating Room Costs,’ also demonstrates how surgeons have direct control over the supplies they use for a specific surgery, either through their preference card (a list of supplies and equipment required for a certain case) or requests made in the operating room. This results in significant price disparities for similar treatments at the same facility.  

Related: How technology is shaping the future of surgery

Therefore, hospitals need to involve surgeons in discussions about current and emerging technologies and products so they can play a role in their healthcare provider’s initiatives to lower the cost of high-quality care. “There are always collaborative efforts between the surgeons, providers, regulators, and insurers to tackle such scenarios. Only through liaison and dialogue can we achieve any kind of success," concludes Dr. Verma. 

Get the latest insights from the healthcare industry straight to your inbox. Subscribe for a bi-weekly roundup of the latest healthcare tech, trends, innovation and patient experience, accompanied by exclusive interviews from the industry’s leaders.

Back to Management

Breast cancer is the most common form of cancer across the world and common risk factors for the disease include age, genetic mutations, personal and family history of breast and ovarian cancer, having dense breasts, being overweight or obese, and an unhealthy lifestyle that includes smoking and alcohol consumption. People who have had radiation therapy, or hormone replacement therapy, also face a heightened risk of developing breast cancer. 

“While breast cancer is much more common in women, it can also affect men. The incidence of breast cancer in men is significantly lower compared to women, but it is not exclusive to one gender. Approximately 0.5 to one per cent of breast cancers occur in men,” Dr. Stephen Grobmyer, Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi. 

Dr. Stephen Grobmyer, Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi

He added that breast cancer was among the top-ranked cancers among men and women in the UAE and the leading cause of cancer deaths in 2019, with an estimated average of 11.6 per cent of cancer deaths per year. The number of breast cancer cases among women is much higher compared to that in men.  

“According to the 2019 Cancer Incidence in the Annual Report of the UAE, there were 875 breast cancer cases in women as opposed to eight cases in men. Creating awareness is one of the most important things that we can do to reduce the burden of breast cancer,” he said. 

Related: Advances in aggressive breast cancer treatments

The well-known recommendation to begin screening for breast cancer at 40 years is based on statistical evidence showing that the risk increases with age, and that earlier detection often leads to better outcomes. However, some women may require more frequent screenings, especially if breast cancer runs in the family, or there is an inherited genetic mutation. It is also important to prioritise healthy lifestyles to reduce overall cancer risk.  

Additionally, technology has greatly improved survival and recovery rates among patients. Dr. Bassel Jallad, Staff Physician at Cleveland Clinic Abu Dhabi, added: “Medical advances in recent years have resulted in the emergence of pioneering diagnostic and therapeutic techniques for breast cancer treatment and have contributed to the high rates of recovery from the disease. Those advances also mean that women who suffer from breast cancer now have a variety of options, depending on their condition.”

 

Dr. Bassel Jallad, Staff Physician at Cleveland Clinic Abu Dhabi

For therapeutic techniques, options include medication to treat breast cancer including hormonal therapy, chemotherapy, and targeted therapies. Other interventions include surgical treatment and radiation therapy, to reduce the risk of local cancer recurrence.  

“We are also now using immunotherapy to treat breast cancer where the immune system is activated to eliminate breast cancer from the body. For patients who require surgery, our multidisciplinary teams often combine removal of the tumour with the reconstruction of the breast and lymphatic system to optimise recovery and limit side effects,” he added.  

Lymphoedema, which is often triggered by breast cancer, axillary lymph node dissection surgery for cancer, or radiation treatment, is a debilitating condition that manifests as acute swelling of the upper arm after metastasised lymph nodes are removed. The condition brings an increased possibility of infection, along with social, mental and physical implications for those already undergoing cancer treatment. One in five patients is prone to developing breast cancer-related lymphoedema and this can be addressed either through lymphedema-preventive super-microsurgery or novel vascularised lymph node transfer. 

Sharing insights into the case of a recent 51-year-old breast cancer patient suffering from lymphoedema who was treated using vascularised lymph node transfer treatment, Dr. Raffi Gurunian, Department Chair and Chief of Plastic Surgery at Cleveland Clinic Abu Dhabi, said: “The patient had had a mastectomy to remove her affected right breast, followed by radiation therapy. Her lymph nodes had also been removed to treat the breast cancer, and when she presented to us, she had swelling in the right arm. 

Related: Busting the myth of male breast cancer

“During her subsequent breast reconstruction procedure, we transferred healthy lymph nodes from her groin area to the right armpit, while also using abdominal tissue to reconstruct her breast, using the DIEP (Deep Inferior Epigastric Perforator) flap technique, one of the specialised technologies available at the Fatima bint Mubarak Center,” he said. 

Dr. Raffi Gurunian, Department Chair and Chief of Plastic Surgery at Cleveland Clinic Abu Dhabi

This is the first case in the UAE involving the usage of vascularised lymph node transfer with a DIEP flap breast reconstruction to treat lymphoedema. “To ensure its success, we made use of a new technology known as the Indocyanine Green machine (ICG machine). This ICG machine uses a florescent dye to detect the perfusion of the blood vessels, allowing us to harvest healthy tissue and lymph nodes for the reconstruction,” he added.  

Cleveland Clinic Abu Dhabi’s Breast Health Clinic’s multidisciplinary cancer programme continues to raise awareness around breast health and cancer prevention alongside the importance of regular screening.  

 

Get the latest insights from the healthcare industry straight to your inbox. Subscribe for a bi-weekly roundup of the latest healthcare tech, trends, innovation and patient experience, accompanied by exclusive interviews from the industry’s leaders.

___

Back to Technology

In the UAE, arthritis affects one in five people and is the top cause of disability globally. Arthritis includes over 100 autoimmune and rheumatic musculoskeletal conditions, and while it is commonly associated with ageing, younger patients are also affected.

World Arthritis Day, held on October 12 annually, emphasises the importance of recognising the symptoms of this painful disease, which can help lead to early intervention. Renowned organisations such as the Middle East Arthritis Foundation (MEAF) host focused events to further raise awareness and assist those who suffer from this debilitating disease.

While traditional treatments such as medications, physiotherapy, and surgery can alleviate symptoms, as World Arthritis Day is observed, we examine some alternatives and advancements that may offer hope for an enhanced quality of life.

Related: Understanding Systemic Juvenile Idiopathic Arthritis and gut health

The use of remote monitoring offers a promising way to decrease hospital visits for arthritic patients through a combination of self-management and telemedicine. With the potential to replace labour-intensive outpatient clinic visits, this could positively impact healthcare utilisation while keeping disease activity low.

Regenerative medicine in arthritis could utilise cell therapy, bioengineering and gene therapy to stimulate the body's natural healing response. A key development is Platelet-Rich Plasma (PRP), derived from a patient's blood, PRP can be used to treat pain, damaged tendons, hair loss and ageing skin. While it can relieve symptoms and boost healing, its effectiveness may vary based on preparation methods and patient factors.

Similar to fat-based PRP, Autologous Micro-fragmented Adipose Tissue (AMAT) involves liposuction to extract fat, which is then injected into areas needing treatment. Studies show improvements in osteoarthritis pain and function, but consistency in AMAT quality remains a challenge.

Stem cell therapy holds great potential for tissue repair and regeneration. The various stem cell types include: embryonic, adult, induced pluripotent, and very small embryonic-like stem cells. Clinical trials are ongoing and the FDA cautions against unproven therapies from for-profit clinics. It emphasises the need for standardised guidelines and further research to discover the full potential of stem cells in arthritis care.

Related: Gen AI may power the next generation of immunotherapies

Surgical options such as Osteochondral Autograft Transplantation Surgery (OATS) and Matrix-Induced Autologous Chondrocyte Implantation (MACI) use a patient's own or donor tissue to repair localised cartilage damage, preventing arthritis progression. Researchers are exploring gene editing tools like CRISPR-Cas9 to create custom-designed cells and gene therapies that target inflammatory proteins in osteoarthritis.

While these treatments in regenerative medicine demonstrate substantial potential, continuous research, protocol refinement, and establishing standardised methodologies are imperative to fully discover their benefits in the field of arthritis care.

The pandemic provided the catalyst for one of the largest and fastest adoptions of technologies in modern history, awakening organisations to the need and uses of video calls for meetings, consultations and service provision and the realisation that reliable telecommunications networks were essential. While the media hype around 5G initially homed in on consumers looking for home entertainment and gaming among other uses, industries are now pivoting to 5G. 

Healthcare is one example where 5G is expected to bring a variety of telemedicine applications, such as remote patient monitoring and care, into the mainstream. It can facilitate remote support for nurses and doctors doing home visits to video stream expert opinion in and out of the home, or for ambulance staff at the scene of a scenario that might need additional support, for surgery when specialist surgeons or the patient cannot be moved but expertise is needed. 

While figuring out how to make the patient experience better right now, it is also very important to think about the future. As hospital operations become increasingly digitalised, it becomes ever more important to have wireless networks that can handle the load from robots, sensors, location solutions, and other connected Internet of Things (IoT) and artificial intelligence (AI)-based technologies.  

Related: Webinar: Digitalisation creates a collaborative environment in Saudi healthcare

Think about the load that is increasingly being placed on networks. There is a continuous flow of vital signs from patients located in a multitude of locations combined with statistics to predict outcomes and deliver tailored care plans.  

There are robots undertaking neurosurgery guided by a surgeon on a different continent — and taking patient temperatures, triaging, and delivering food. Meanwhile, telehealth consultations during virtual surgeries are enriched with added data input from wearables relaying patient vital signs to people inside and outside the operating room in real time. Wearables are guiding physiotherapy programmes, alerting care providers to patient falls, and keeping chronic patients like diabetics well for longer with personalised programmes. 

Healthcare professionals should not be isolated or unable to access the information or advice they need on the spot. High-quality healthcare devices with Wi-Fi 6 and 5G connectivity, Bluetooth, walkie-talkie calls, instant messaging, high-quality touch screens, cameras and mics, and the ability to quickly access and share patient records and treatment notes should be a normal and standard expectation. 

Related: Strategies to lead the healthcare industry in the era of digital transformation

Telehealth has increased the comfort and convenience of care for patients everywhere. People no longer need to attend a hospital or clinic for every appointment — or to get a prescription renewal or specialist referral. And they no longer need to be concerned with commuting or wait times. They simply need to be virtually accessible for their scheduled appointment. Heightened visibility into the potential of telehealth, chatbots, and remote patient monitoring have healthcare providers trying to determine the right care model and service delivery balance moving forward.  

Though most people think of telehealth as a provider consulting with an at-home patient, we could see more inpatient oversight and care via telehealth. Recently, a hospital was using enterprise-grade handheld mobile computers to connect patients with their relatives by video call. There were more than 14,000 virtual visits conducted in its first year alone.  

Time for 5G to join forces with Wi-Fi 

Think about what will happen if we keep placing that demand on Wi-Fi networks — networks that are overloaded simply by a growing number of connected smartphones, clinical mobile computers, and tablets. We cannot put all our eggs in one basket. Ideally, everyone in healthcare should be talking about 5G and what it is going to take to get healthcare operational and information technology systems migrated to 5G networks inside and outside the four walls.  

With speeds 100 times faster than 4G and ultra-low latency, 5G has the ability to handle many more connections without faltering. 5G is imperative for the volume and sensitivity of new healthcare delivery data — an enabler and catalyst for better outcomes. 

I know you might think I am ahead of the times on this one considering many parts of the world are still on 3G or not yet able to access 5G networks. Plus, healthcare leaders have spent a fortune on Wi-Fi infrastructure that no one wants to rip and replace. But I am not saying 5G is an urgent action item — just an urgent topic of discussion.  

If anything, you should be asking technology providers about what it will take to get a private wireless network online in general. Whether it is 4G or 5G right now really does not matter because cellular connectivity offers many advantages over Wi-Fi when it comes to network stability, predictability and even security, which patients will be keen on with electronic patient record system use rising.  

Standing up a cellular network that you can fully control within your facilities is going to be table stakes sooner than you think. And you will not have to replace anything as it will work alongside your Wi-Fi networks. The Wi-Fi could be reserved for patient/guest use while private wireless network access could be prioritised for staff communications, telehealth, robotic surgeries, virtual wards, patient monitoring and more.  

The pandemic accelerated healthcare technology adoption at unprecedented rates, and this looks set to continue. As care delivery becomes increasingly sophisticated both inside and outside hospital facilities, the load on our digital infrastructure will increase. Leaders should be considering 5G-enabled devices and facilities a significant part of the future of healthcare. 

Lorna Hopkin is the Healthcare Solutions Specialist, EMEA, Zebra Technologies. 

 

Get the latest insights from the healthcare industry straight to your inbox. Subscribe for a bi-weekly roundup of the latest healthcare tech, trends, innovation and patient experience, accompanied by exclusive interviews from the industry’s leaders.

Back to Technology

Healthcare providers are known to serve patients and improve their quality of life, however addressing mental health issues of its own employees is often overlooked.

This can have a profound impact on both employees and the organisation’s bottom line. As Omnia Health observes World Mental Health Day on October 10, we speak to Maham Rasheed, Dubai Health Authority (DHA) licensed Clinical Psychologist, Nabta Health, to understand how mental health neglect affects financial and operations costs in healthcare business management in the UAE.

Rasheed explains that there is a shortage of ongoing research when it comes to the impact of mental health in the UAE, however based on findings from COVID case studies, the Dubai Health Authority (DHA), discovered that the prevalence of mental health issues among the working population in Dubai was approximately 21 per cent.

Related: New FDA-approved drug brings hope for postpartum depression

Nabta Health recently conducted its own research to shed more light on the topic. “Our findings revealed that not prioritising an employee’s mental health can have several negative consequences that hinder productivity and financial growth within healthcare businesses. This creates a domino effect across financial management, operational efficiency, morale, job satisfaction, productivity, patient satisfaction, standard of care, and may drive employees towards clinical malpractice,” says Rasheed.

Figures from PwC Middle East’s recent report titled, “Why GCC Governments Should Invest More in Mental Health,” highlighted that mental illness in the GCC region led to at least 3.7 million productive working days lost annually, which is equivalent to Dh13 billion loss in business.

“To the GCC economy, that translates to Dh48 billion per year. In addition, a recent survey by McKinsey indicated that two-thirds of GCC respondents reported symptoms of poor mental health and well-being or had a mental health condition at least once in their lives. This is a staggering number of mental health-related problems in healthcare businesses,” explains Rasheed.

To understand how healthcare businesses are affected, start with the employee. Chronic stress and anxiety may result in frequent sick leaves and medical consultations, resulting in increased healthcare costs and reduced productivity.

“It also means high turnover, and in some cases, legal costs. The World Health Organisation discovered that in the Middle East, mental health disorders are the leading cause of disability, and they account for 60 per cent of all healthcare costs, which are passed from insurance onto companies,” says the clinical psychologist.

Related: How prioritising mental health support can lead to a better work environment

To overcome this challenge, mental health requires a holistic approach, explains Rasheed. Introducing mental health programmes that offer counselling workshops and resources to help employees manage stress, anxiety and other mental health issues effectively is the first step. Secondly, to overcome stigma associated with mental health, it is important to educate and encourage staff to speak up and seek help without the fear of judgement.

Workplace flexibility is an important component as well. It provides struggling employees the opportunity to prioritise their well-being.

“Lastly, organisations should train managers and staff to recognise the signs of mental health issues. Employee assistance programmes should also be introduced. This should include support services to ensure employees have access to professional assistance when facing mental health difficulties,” she concludes.

 

Stigma about mental health

Dr. Mohammed Yousef, Specialist Psychiatrist at Aster Clinic, Muteena

Stigma affects health professionals’ desire to seek help or address mental health issues, which can result in an overreliance on self-treatment and low peer support. Initial reluctance to seek help may also result in decreased productivity and affect individual health.

In health facilities, the manifestation of stigma is widely documented ranging from outright denial of care and provision of substandard care. The seven types of stigmas are public, self, perceived, label, structural, health prevention, and associative. To prevent stigma among healthcare workers, leaders should know the facts, educate themselves and others about mental illness, focus on positive aspects, and provide the necessary support.

 

 

Get the latest insights from the healthcare industry straight to your inbox. Subscribe for a bi-weekly roundup of the latest healthcare tech, trends, innovation and patient experience, accompanied by exclusive interviews from the industry’s leaders.

Back to Management

In the relentless global battle against cancer, generative artificial intelligence (Gen AI) has emerged as a powerful tool in oncology’s arsenal. With the capacity to analyse vast datasets, simulate complex molecular interactions, and tailor treatments to individual patients, Gen AI is reshaping the landscape of immunotherapy — an essential frontier in cancer treatment.  

In a groundbreaking accomplishment, British biotech company Etcembly has tapped into the potential of a ChatGPT-like Gen AI tool to create a cutting-edge immunotherapy drug to treat cancer.   

The new drug ETC-101 falls under the category of bispecific T-cell engagers. It derives its power from the natural T-cell receptors (TCRs), which act as molecular couriers, directing immune 'killer' T-cells towards cancer cells with the intention of annihilating them. However, a glaring issue arises when it comes to natural TCRs — their weak affinity for cancer cells and their unfortunate ability to recognise targets in healthy cells. The solution, according to Ectembly, is extensive molecular engineering to fashion TCRs with greater sensitivity and selectivity to function effectively as drugs. 

Related: Insurtech chatbots: Synergised digital solution for enhancing patient experience

Central to this discovery is EMLy, an advanced supercomputer armed with the latest machine-learning algorithms. EMLy scours through massive datasets, decoding the intricate 'language' of TCRs and identifying the optimal receptor for a specific target. Following this, a generative large language model (LLM), akin to ChatGPT, steps in to 'rewrite' the genetic code of the TCR, ensuring it achieves maximum potency. 

Michelle Teng, Co-founder and CEO, Ectembly 

The culmination of this journey takes place in the laboratory, where the newly crafted genetic code is put to the test, creating real-life TCR-based drugs, of which ETC-101 stands as a prime example. This therapy has been tailored to target PRAME, a molecule that pervades many cancers known for its very low survival rates. ETC-101's lead drug binds to PRAME with a million-fold greater affinity than natural TCRs, all while bypassing healthy cells. This suggests that the treatment is set to be incredibly potent with minimal side effects. What is even more astonishing is the speed at which this achievement has unfolded, with ETC-101's development taking a mere 11 months, a remarkable contrast to the conventional two-year timeline for TCR discovery and engineering processes. 

“Etcembly was born from our desire to bring together two concepts that are ahead of the scientific mainstream — TCRs and generative AI — to design the next generation of immunotherapies,” says co-founder and CEO, Michelle Teng. “This is an area that’s close to my heart because I suffer from an autoimmune disease myself, and I undergo immunotherapy.”  

Related: Beyond the hype: Generative AI and healthcare in the Middle East

The hype around Gen AI is vast and well-deserved, but concerns remain over its suitability in healthcare, mostly around its future impact and vulnerability to hidden bias in data sets. ChatGPT provides responses centred on what is most likely to come next based on the input it receives, which can be problematic, according to augmented intelligence firm Squirro’s CEO, Dr. Dorian Selz.  

“ChatGPT is a ‘stochastic’ model, as it generates responses based on probability rather than determinism. But it is limited by the data on which it was trained, which can be problematic,” he says. "This means it can lack context and deliver results that do not make sense, are irrelevant, or are not compliant with enterprise codes. There are legitimate questions about which data is used to produce content and how users' access rights to information are correctly managed. Generative AI can be a powerful tool, but to add genuine and tangible value, it must be integrated into a semantic enterprise search engine and trained on internal data.” 

On that note, Ectembly’s Teng agrees that existing TCR trials are based on a predominantly European population. That’s a limitation and extremely short-sighted, she says, pointing to the wider issue of collating diverse data sets. Gen AI runs on limited data and therefore exhibits bias. This means that the very tool that may be called out for its bias can be used to address bias in healthcare. “We are a very cosmopolitan society. We need a platform like generative AI to scale the discovery. We want to make it tailorable for other ethnic groups. This is the main ethos of our company — it is immunotherapy for everyone; not one size fits all.”  

The next step for the company is comprehensive lab testing before it can enter the market. Teng is planning to initiate clinical trials as early as 2025 while working on new immunotherapy drugs to tackle melanoma, lung cancer, and autoimmune diseases like arthritis. The company is also preparing for the next round of investment fundraising.  

Etcembly's transformative AI technology is shattering the barriers that have long impeded the discovery and engineering of TCR candidates. It’s an example of how Gen AI could speed up drug discovery and delivery, ushering in a new era of medical progress. 

 

Access the must-read eBook on AI here to discover perspectives on its transformative role in the healthcare industry.

___
Back to Technology